In this study, we reported the proteomic profiles of pediatric bone marrow-derived AML cells at diagnosis in three differential comparison strategies: (1) core binding factor (CBF; t(8;21), inv(16)) AML vs. non-CBF AML; (2) MRD1-positive vs. MRD1-negative status; and (3) in vitro chemosensitivity of Ara-C LC50-high vs. low level. This evidence concerns the gene CEBPZ and acute myeloid leukemia.